JOP20200231A1 - ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها - Google Patents

ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها

Info

Publication number
JOP20200231A1
JOP20200231A1 JOP/2020/0231A JOP20200231A JOP20200231A1 JO P20200231 A1 JOP20200231 A1 JO P20200231A1 JO P20200231 A JOP20200231 A JO P20200231A JO P20200231 A1 JOP20200231 A1 JO P20200231A1
Authority
JO
Jordan
Prior art keywords
compounds
methods
pharmaceutical compositions
ppar agonists
ppar
Prior art date
Application number
JOP/2020/0231A
Other languages
English (en)
Inventor
Samajdar Susanta
Senaiar Ramesh
Takahashi Taisuke
Lagu Bharat
Patane Michael
Miura Masanori
Downes Michael
Kluge Arthur
M Evans Ronald
Kumar Panigrahi Sunil
Original Assignee
Salk Inst Biological Studies
Mitobridge Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57200096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JOP20200231(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Salk Inst Biological Studies, Mitobridge Inc filed Critical Salk Inst Biological Studies
Publication of JOP20200231A1 publication Critical patent/JOP20200231A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

يتم هنا توفير مركبات وتراكيب مفيدة في زيادة نشاط PPAR?. تعتبر المركبات والتراكيب المقدمة في هذه الوثيقة مفيدة لعلاج أمراض مرتبطة بـ PPAR? (على سبيل المثال، أمراض العضلات، وأمراض الأوعية الدموية، وأمراض مزيلة للميلان، والأمراض الاستقلابية).
JOP/2020/0231A 2015-10-07 2020-09-14 ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها JOP20200231A1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562238629P 2015-10-07 2015-10-07
US201562243263P 2015-10-19 2015-10-19
US201662352348P 2016-06-20 2016-06-20

Publications (1)

Publication Number Publication Date
JOP20200231A1 true JOP20200231A1 (ar) 2022-10-30

Family

ID=57200096

Family Applications (3)

Application Number Title Priority Date Filing Date
JOP/2016/0217A JO3738B1 (ar) 2015-10-07 2016-10-06 ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
JOP/2020/0230A JOP20200230A1 (ar) 2015-10-07 2020-09-14 ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
JOP/2020/0231A JOP20200231A1 (ar) 2015-10-07 2020-09-14 ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JOP/2016/0217A JO3738B1 (ar) 2015-10-07 2016-10-06 ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
JOP/2020/0230A JOP20200230A1 (ar) 2015-10-07 2020-09-14 ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها

Country Status (26)

Country Link
US (5) US10399958B2 (ar)
EP (3) EP3795566B1 (ar)
JP (2) JP6657413B2 (ar)
KR (2) KR20180095797A (ar)
CN (3) CN113004205A (ar)
AU (3) AU2016333963C1 (ar)
BR (1) BR112018006866B1 (ar)
CA (1) CA3000431A1 (ar)
CO (1) CO2018004473A2 (ar)
DK (1) DK3359528T3 (ar)
EA (1) EA037371B1 (ar)
ES (2) ES2949852T3 (ar)
HK (1) HK1257907A1 (ar)
HU (1) HUE058154T2 (ar)
IL (3) IL258225B (ar)
JO (3) JO3738B1 (ar)
MA (2) MA52098A (ar)
MX (2) MX2020011100A (ar)
PH (1) PH12018500762A1 (ar)
PL (1) PL3359528T3 (ar)
PT (1) PT3359528T (ar)
SG (1) SG10201906400SA (ar)
TW (3) TWI730408B (ar)
UA (1) UA122237C2 (ar)
WO (1) WO2017062468A1 (ar)
ZA (4) ZA201802029B (ar)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3359528T (pt) 2015-10-07 2022-04-07 Salk Inst Biological Studies Agonistas de ppar, compostos, composições farmacêuticas e métodos de utilização dos mesmos
WO2017180818A1 (en) 2016-04-13 2017-10-19 Mitobridge, Inc. Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
HUE055678T2 (hu) * 2016-10-05 2021-12-28 Mitobridge Inc PPAR agonista vegyületek kristályos és só alakjai
SG11201901925RA (en) * 2016-10-05 2019-04-29 Mitobridge Inc Methods of treating acute kidney injury
WO2021046081A1 (en) * 2019-09-05 2021-03-11 Rush University Medical Center Methods and compositions for treatment of demyelinating disorders
US11634387B2 (en) 2019-09-26 2023-04-25 Abionyx Pharma Sa Compounds useful for treating liver diseases
WO2022189856A1 (en) 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
AU2022286415A1 (en) 2021-06-02 2023-12-14 Astellas Pharma Inc. Methods of use of ppar agonist compounds and pharmaceutical compositions thereof
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease
EP4230196A1 (en) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Compounds for use in the treatment of dystrophinopathies

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4228281A (en) 1977-09-23 1980-10-14 Ciba-Geigy Corporation Dicarboxylic acids containing triazine rings
DE4123341A1 (de) * 1991-07-15 1993-01-21 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
GB9511694D0 (en) 1995-06-09 1995-08-02 Fujisawa Pharmaceutical Co Benzamide derivatives
AU773273B2 (en) 1999-02-26 2004-05-20 Bristol-Myers Squibb Company Novel sulfonamide compounds and uses thereof
GB9919413D0 (en) 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
PL361054A1 (en) 2000-08-17 2004-09-20 Pfizer Inc. Substituted imidazoles as tafia inhibitors
WO2004020409A1 (en) * 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles having anti-diabetic activity
EP1553075B1 (en) 2002-10-03 2013-08-14 Ono Pharmaceutical Co., Ltd. Lpa receptor antagonists
WO2004060367A1 (en) 2002-12-30 2004-07-22 Fujisawa Pharmaceutical Co., Ltd. Imidazole and triazole derivatives useful as selective cox-1 inhibitors
EP1670446A2 (en) 2003-09-26 2006-06-21 Japan Tobacco Inc. Method of inhibiting remnant lipoprotein production
RU2007112688A (ru) 2004-09-06 2008-10-20 Ф.Хоффманн-Ля Рош Аг (Ch) Производные 4-аминометилбензамина и их применение в качестве ингибиторов фактора viia
BRPI0606997A2 (pt) 2005-02-15 2009-07-28 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os contêm, método para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas ppar(delta) e/ou ppar(alfa) e utilização dos compostos
CA2621406A1 (en) 2005-09-07 2007-03-15 Plexxikon, Inc. Pparactive compounds
WO2007089857A2 (en) 2006-01-30 2007-08-09 Transtech Pharma, Inc. Substituted imidazole derivatives and their use as ptpase inhibitors
US20100261758A1 (en) 2006-03-28 2010-10-14 Novartis Ag Heterocyclic amides for use as pharmaceuticals
CN102643248A (zh) 2006-04-18 2012-08-22 日本化学医药株式会社 过氧化物酶体增殖剂激活受体δ的激活剂
DE102006023336A1 (de) 2006-05-18 2007-11-22 Merck Patent Gmbh 1,5-Diphenyl-pyrazole II
CN101085772A (zh) * 2006-06-07 2007-12-12 上海艾力斯医药科技有限公司 一类具有PPARγ激动剂活性的化合物及其应用
JPWO2008093639A1 (ja) 2007-01-29 2010-05-20 武田薬品工業株式会社 ピラゾール化合物
GB2460784A (en) 2007-03-07 2009-12-16 Dong A Pharmtech Co Ltd Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators,method of the same,and pharmaceutical composition
JP2008285452A (ja) 2007-05-21 2008-11-27 Ono Pharmaceut Co Ltd ＰＰＡＲα／γデュアルアゴニストおよび糖尿病治療薬を組み合わせてなる医薬
CA2710764A1 (en) 2007-12-28 2009-07-09 The Salk Institute For Biological Studies Methods for enhancing muscle performance and tone
EP2890313B1 (en) 2012-08-28 2016-09-21 KOC Universitesi Bone plate
EP2981522A4 (en) 2013-04-05 2016-08-31 Salk Inst For Biological Studi ANTAGONISTS OF PPAR
EP3756661A1 (en) 2013-09-09 2020-12-30 vTv Therapeutics LLC Use of a ppar-delta agonist for treating muscle atrophy
WO2016057658A1 (en) * 2014-10-08 2016-04-14 Mitobridge, Inc. Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
WO2016057322A1 (en) * 2014-10-08 2016-04-14 Salk Institute For Biological Studies Ppar agonists and methods of use thereof
PT3359528T (pt) 2015-10-07 2022-04-07 Salk Inst Biological Studies Agonistas de ppar, compostos, composições farmacêuticas e métodos de utilização dos mesmos
WO2017180818A1 (en) 2016-04-13 2017-10-19 Mitobridge, Inc. Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
SG11201901925RA (en) 2016-10-05 2019-04-29 Mitobridge Inc Methods of treating acute kidney injury
HUE055678T2 (hu) * 2016-10-05 2021-12-28 Mitobridge Inc PPAR agonista vegyületek kristályos és só alakjai

Also Published As

Publication number Publication date
AU2020281069B2 (en) 2022-10-27
EP3359528B1 (en) 2022-01-12
TW202012375A (zh) 2020-04-01
KR20180095797A (ko) 2018-08-28
JP6866514B2 (ja) 2021-04-28
US10399958B2 (en) 2019-09-03
UA122237C2 (uk) 2020-10-12
ES2906379T3 (es) 2022-04-18
ZA202003664B (en) 2022-08-31
WO2017062468A1 (en) 2017-04-13
AU2019283837B2 (en) 2020-12-24
AU2019283837A1 (en) 2020-01-16
JP2020075939A (ja) 2020-05-21
CN108349904B (zh) 2021-08-31
IL275387B (en) 2021-08-31
PT3359528T (pt) 2022-04-07
AU2016333963A1 (en) 2018-04-12
TW201722919A (zh) 2017-07-01
CA3000431A1 (en) 2017-04-13
EP3795566A1 (en) 2021-03-24
HUE058154T2 (hu) 2022-07-28
MX2020011100A (es) 2022-05-23
US10906885B2 (en) 2021-02-02
IL275387A (en) 2020-07-30
US10479775B1 (en) 2019-11-19
US20200157074A1 (en) 2020-05-21
JP2018534355A (ja) 2018-11-22
US20190084958A1 (en) 2019-03-21
SG10201906400SA (en) 2019-08-27
KR20210126150A (ko) 2021-10-19
US20190337920A1 (en) 2019-11-07
CN108349904A (zh) 2018-07-31
WO2017062468A8 (en) 2017-05-11
ZA202003662B (en) 2022-08-31
ES2949852T3 (es) 2023-10-03
IL275392B (en) 2022-05-01
TWI730408B (zh) 2021-06-11
EP3770146A1 (en) 2021-01-27
EA201890776A1 (ru) 2018-09-28
IL258225A (en) 2018-05-31
MA52648A (fr) 2021-10-13
BR112018006866B1 (pt) 2023-11-21
MA52098A (fr) 2021-01-27
TW201943705A (zh) 2019-11-16
DK3359528T3 (en) 2022-03-07
JP6657413B2 (ja) 2020-03-04
JOP20200230A1 (ar) 2022-10-30
TWI742479B (zh) 2021-10-11
AU2020281069A1 (en) 2021-01-07
AU2016333963C1 (en) 2021-05-27
ZA201802029B (en) 2022-01-26
ZA202003663B (en) 2022-08-31
CN113004205A (zh) 2021-06-22
CO2018004473A2 (es) 2018-09-20
IL275392A (en) 2020-07-30
US11578052B2 (en) 2023-02-14
CN113024467A (zh) 2021-06-25
IL258225B (en) 2021-08-31
PL3359528T3 (pl) 2022-05-30
PH12018500762A1 (en) 2018-10-29
JO3738B1 (ar) 2021-01-31
EP3359528A1 (en) 2018-08-15
EP3795566B1 (en) 2023-04-19
AU2016333963B2 (en) 2021-01-07
TWI730006B (zh) 2021-06-11
MX2020011099A (es) 2022-05-23
US20230373948A1 (en) 2023-11-23
US20210253549A1 (en) 2021-08-19
BR112018006866A2 (pt) 2018-10-16
HK1257907A1 (zh) 2019-11-01
EA037371B1 (ru) 2021-03-19

Similar Documents

Publication Publication Date Title
JOP20200230A1 (ar) ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
MX2018012538A (es) Agonistas del receptor activado por proliferador de peroxisoma (ppar), compuestos, composiciones farmaceuticas y metodos para usar los mismos.
SA518391624B1 (ar) Ror- منظمات جاما
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
TW201613901A (en) New compounds
MX2017016134A (es) Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
WO2015171610A3 (en) Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
MX2017009417A (es) Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
WO2016057658A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
WO2018115432A3 (en) COMPOUNDS FOR THE TREATMENT OF BOVINE OR PORCINE RESPIRATORY DISEASE
PH12017500261A1 (en) Substituted bicyclic compounds
PH12016502243A1 (en) Pharmaceutical compositions for treating infectious diseases
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
WO2016057660A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
MX2017006491A (es) Composiciones y métodos para la modulación de la actividad at2r.
MX2018004295A (es) Compuestos, composiciones farmáceuticas y métodos de uso de agonistas de ppar.
IL260009B (en) Novel bicyclic-compounds for use as a medicament, in particular for treatment of parkinson's disease
EA201992619A3 (ru) Агонисты ppar, соединения, фармацевтические композиции и способы их применения